KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Total Debt (2016 - 2026)

Bristol Myers Squibb has reported Total Debt over the past 18 years, most recently at $44.5 billion for Q1 2026.

  • Quarterly Total Debt fell 10.56% to $44.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $44.5 billion through Mar 2026, down 10.56% year-over-year, with the annual reading at $45.1 billion for FY2025, 9.14% down from the prior year.
  • Total Debt was $44.5 billion for Q1 2026 at Bristol Myers Squibb, down from $45.1 billion in the prior quarter.
  • Over five years, Total Debt peaked at $55.7 billion in Q1 2024 and troughed at $37.6 billion in Q3 2023.
  • The 5-year median for Total Debt is $45.0 billion (2022), against an average of $44.9 billion.
  • Year-over-year, Total Debt dropped 15.88% in 2023 and then surged 47.18% in 2024.
  • A 5-year view of Total Debt shows it stood at $39.3 billion in 2022, then increased by 1.15% to $39.8 billion in 2023, then increased by 24.83% to $49.6 billion in 2024, then fell by 9.14% to $45.1 billion in 2025, then dropped by 1.44% to $44.5 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Total Debt are $44.5 billion (Q1 2026), $45.1 billion (Q4 2025), and $49.0 billion (Q3 2025).